Literature DB >> 27348802

Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014.

Lindsey M Weiner1, Scott K Fridkin1, Zuleika Aponte-Torres1, Lacey Avery1, Nicole Coffin1, Margaret A Dudeck1, Jonathan R Edwards1, John A Jernigan1, Rebecca Konnor1, Minn M Soe1, Kelly Peterson1, L Clifford McDonald1.   

Abstract

BACKGROUND: Healthcare-associated antibiotic-resistant (AR) infections increase patient morbidity and mortality and might be impossible to successfully treat with any antibiotic. CDC assessed healthcare-associated infections (HAI), including Clostridium difficile infections (CDI), and the role of six AR bacteria of highest concern nationwide in several types of healthcare facilities.
METHODS: During 2014, approximately 4000 short-term acute care hospitals, 501 long-term acute care hospitals, and 1135 inpatient rehabilitation facilities in all 50 states reported data on specific infections to the National Healthcare Safety Network. National standardized infection ratios and their percentage reduction from a baseline year for each HAI type, by facility type, were calculated. The proportions of AR pathogens and HAIs caused by any of six resistant bacteria highlighted by CDC in 2013 as urgent or serious threats were determined.
RESULTS: In 2014, the reductions in incidence in short-term acute care hospitals and long-term acute care hospitals were 50% and 9%, respectively, for central line-associated bloodstream infection; 0% (short-term acute care hospitals), 11% (long-term acute care hospitals), and 14% (inpatient rehabilitation facilities) for catheter-associated urinary tract infection; 17% (short-term acute care hospitals) for surgical site infection, and 8% (short-term acute care hospitals) for CDI. Combining HAIs other than CDI across all settings, 47.9% of Staphylococcus aureus isolates were methicillin resistant, 29.5% of enterococci were vancomycin resistant, 17.8% of Enterobacteriaceae were extended-spectrum beta-lactamase phenotype, 3.6% of Enterobacteriaceae were carbapenem resistant, 15.9% of Pseudomonas aeruginosa isolates were multidrug resistant, and 52.6% of Acinetobacter species were multidrug resistant. The likelihood of HAIs caused by any of the six resistant bacteria ranged from 12% in inpatient rehabilitation facilities to 29% in long-term acute care hospitals.
CONCLUSIONS: Although there has been considerable progress in preventing some HAIs, many remaining infections could be prevented with implementation of existing recommended practices. Depending upon the setting, more than one in four of HAIs excluding CDI are caused by AR bacteria. IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Physicians, nurses, and healthcare leaders need to consistently and comprehensively follow all recommendations to prevent catheter- and procedure-related infections and reduce the impact of AR bacteria through antimicrobial stewardship and measures to prevent spread. No claim to original US government works © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Year:  2016        PMID: 27348802     DOI: 10.1111/ajt.13893

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  10 in total

1.  Implementation of An Antibiotic Stewardship Intervention to Reduce Prescription of Fluoroquinolones: A Human Factors Analysis in Two Intensive Care Units.

Authors:  Pascale Carayon; Teresa Thuemling; Vishala Parmasad; Songtao Bao; John O'Horo; Nicholas T Bennett; Nasia Safdar
Journal:  J Patient Saf Risk Manag       Date:  2021-06-22

2.  Identifying asymptomatic spreaders of antimicrobial-resistant pathogens in hospital settings.

Authors:  Sen Pei; Fredrik Liljeros; Jeffrey Shaman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

3.  Carbapenem antibiotic stress increases blaKPC -2 gene relative copy number and bacterial resistance levels of Klebsiella pneumoniae.

Authors:  Huimin Chen; Na Li; Fang Wang; Lei Wang; Wei Liang
Journal:  J Clin Lab Anal       Date:  2022-06-19       Impact factor: 3.124

Review 4.  Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections.

Authors:  Jan T Poolman
Journal:  NPJ Vaccines       Date:  2020-09-11       Impact factor: 7.344

5.  Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.

Authors:  Angelica Zhang; Jeffrey L Veesenmeyer; Alan R Hauser
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

6.  Antibiotic Use and Presumptive Pathogens in the Veterans Affairs Healthcare System.

Authors:  Christine Tedijanto; McKenna Nevers; Matthew H Samore; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 9.079

7.  Incentivizing hospital infection control.

Authors:  Sarah E Drohan; Simon A Levin; Bryan T Grenfell; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-11       Impact factor: 11.205

8.  Surgical site infections caused by multi-drug resistant organisms: a case-control study in general surgery.

Authors:  Diego Foschi; Al'ona Yakushkina; Francesco Cammarata; Giulia Lamperti; Francesco Colombo; Sara Rimoldi; Spinello Antinori; Gianluca M Sampietro
Journal:  Updates Surg       Date:  2022-03-19

9.  Decreasing ICU-associated Clostridioides difficile infection through fluoroquinolone restriction, the FIRST trial: a study protocol.

Authors:  Nasia Safdar; Vishala Parmasad; Roger Brown; Pascale Carayon; Alexander Lepak; John C O'Horo; Lucas Schulz
Journal:  BMJ Open       Date:  2021-06-29       Impact factor: 2.692

10.  A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.

Authors:  Lynn E Connolly; Valerie Riddle; Deborah Cebrik; Eliana S Armstrong; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.